Advancing Vaccine Science to Improve Tuberculosis Treatment Outcomes for People Living With or Without HIV (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement is to invite applications for innovative clinical, and preclinical/translational research to develop therapeutic vaccine strategies to improve treatment outcomes of active tuberculosis (TB) in the presence or absence of HIV co-infection.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • AIDS Application Due Date(s):  July 28, 2020

​RFA-AI-20-010 Expiration Date July 29, 2020

Agency Website



Amount Description

Application budgets are limited to $800,000 in direct costs per year, but also need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Funding Type





Medical - Clinical Science
Medical - Translational

External Deadline

July 28, 2020